Key facts
Iambic Therapeutics, Inc.
New Form D on file · 2026-04-08 · the record
What the record says
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 759 filings in Biotechnology, totalled by week. The dot is this raise, $27.77M, on the same scale — one filing against the whole group's total, so it sits low by construction.
The issuer on the SEC's record
- Business address on fileSan Diego, CASEC record
- Fiscal year endsDecember 31SEC record
What else this issuer has filed
By form type: D ×5 · D/A ×2.
| Form | Filed | On EDGAR |
|---|---|---|
| D | 2026-09-09 | open |
| D | 2026-04-08 | open |
| D | 2025-11-21 | open |
| D/A | 2024-06-06 | open |
| D/A | 2024-05-07 | open |
| D | 2024-04-25 | open |
| D | 2023-10-12 | open |
Want the whole picture on Iambic Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Iambic Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Iambic Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The 7 most recent of 7 filings on CIK 0001997038, filed as Iambic Therapeutics, Inc.. Read from the SEC's own submissions feed for this issuer, not from a third party. Incorporated in DE. Full history on sec.gov.
Company officers on record
Thomas Miller is named as Executive Officer and Director on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 8 April 2026, one of 12 people that filing names.
Fred Manby is named as Executive Officer and Director on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 8 April 2026, one of 12 people that filing names.
Neil Josephson is named as Executive Officer on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 8 April 2026, one of 12 people that filing names.
Michael Secora is named as Executive Officer on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 8 April 2026, one of 12 people that filing names.
Jishnu Bhattacharjee is named as Director on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 8 April 2026, one of 12 people that filing names.
Evan Rachlin is named as Director on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 8 April 2026, one of 12 people that filing names.
R. Jacob Vogelstein is named as Director on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 8 April 2026, one of 12 people that filing names.
Mary Tagliaferri is named as Director on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 8 April 2026, one of 12 people that filing names.
William Rastetter is named as Director on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 8 April 2026, one of 12 people that filing names.
Kurt von Emster is named as Director on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 8 April 2026, one of 12 people that filing names.
Shalini Sharp is named as Director on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 8 April 2026, one of 12 people that filing names.
Pete Olson is named as Executive Officer on the Form D that Iambic Therapeutics, Inc. filed with the SEC on 8 April 2026, one of 12 people that filing names.
12 people named on the filing — 5 holding an executive role and 7 as directors only.
Named as of the 2026-04-08 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
- 12 people named on the filing — 5 holding an executive role and 7 as directors only.
No investor is drawn from a Form D — the form states how many invested and never who.
The full profile
Source Check, INVEST, RECRUIT and Press Requests on Iambic Therapeutics, Inc.
- Source Check — verify Thomas Miller's other claims against the registers that hold them.
- INVEST — size up this raise on the figures the filing states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Thomas Miller for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Iambic Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Iambic Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. FoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.